Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, Wooning M, Chapple C. Khullar V, et al. Among authors: angulo jc. Eur Urol. 2013 Feb;63(2):283-95. doi: 10.1016/j.eururo.2012.10.016. Epub 2012 Nov 6. Eur Urol. 2013. PMID: 23182126 Clinical Trial.
Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.
Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C, Siddiqui E, Martin NE. Nitti VW, et al. Among authors: angulo jc. Int J Clin Pract. 2013 Jul;67(7):619-32. doi: 10.1111/ijcp.12194. Epub 2013 May 21. Int J Clin Pract. 2013. PMID: 23692526 Free PMC article.
Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective.
Angulo JC, Sánchez-Ballester F, Peral C, Rejas J, Ramos J, Snedecor SJ, Sudharshan L, Liu S, Luo X. Angulo JC, et al. Actas Urol Esp. 2016 Oct;40(8):513-22. doi: 10.1016/j.acuro.2015.11.012. Epub 2016 Mar 14. Actas Urol Esp. 2016. PMID: 26988624 English, Spanish.
Treatment of male stress urinary incontinence with the adjustable transobturator male system: Outcomes of a multi-center Iberian study.
Angulo JC, Cruz F, Esquinas C, Arance I, Manso M, Rodríguez A, Pereira J, Ojea A, Carballo M, Rabassa M, Teyrouz A, Escribano G, Rodríguez E, Teba F, Celada G, Madurga B, Álvarez-Ossorio JL, Marcelino JP, Martins FE. Angulo JC, et al. Neurourol Urodyn. 2018 Apr;37(4):1458-1466. doi: 10.1002/nau.23474. Epub 2018 Jan 9. Neurourol Urodyn. 2018. PMID: 29315765
Artificial urinary sphincter or a second adjustable transobturator male system offer equivalent outcomes in patients whom required revision on the initial ATOMS device: An international multi-institutional experience.
Angulo JC, Schönburg S, Giammò A, Queissert F, Gonsior A, González-Enguita C, Martins FE, Rourke K, Cruz F. Angulo JC, et al. Neurourol Urodyn. 2021 Mar;40(3):897-909. doi: 10.1002/nau.24646. Epub 2021 Mar 1. Neurourol Urodyn. 2021. PMID: 33645867
315 results